References

zdor

Проблемы здоровья и экологии

Health and Ecology Issues

2220-09672708-6011

Gomel State Medical University

10.51523/2708-6011.2011-8-1-18

zdor-1071

Research Article

КЛИНИЧЕСКАЯ МЕДИЦИНА

CLINICAL MEDICINE

НЕИНВАЗИВНАЯ ДИАГНОСТИКА НЕАЛКОГОЛЬНОГО СТЕАТОГЕННОГО ГЕПАТИТА

NONINVASIVE DIAGNOSTICS OF NON-ALCOHOLIC STEATOHEPATITIS

Калинин

А. Л.

Kalinin

A. L.

noemail@neicon.ru

Цитко

Е. В.

Tsitko

E. V.

noemail@neicon.ru

Сницаренко

Е. Н.

Snitsarenko

E. N.

noemail@neicon.ru

Хватик

Т. В.

Hvatik

T. V.

noemail@neicon.ru

Гомельский государственный медицинский университетGomel State Medical University

Республиканский научно-практический центр радиационной медицины и экологии человекаRepublican Research Centre for Radiation Medicine and Human Ecology

2011

28032011

0195102

2011

Калинин А.Л., Цитко Е.В., Сницаренко Е.Н., Хватик Т.В.

Kalinin A.L., Tsitko E.V., Snitsarenko E.N., Hvatik T.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.gsmu.by/jour/article/view/1071

Неалкогольная жировая болезнь печени (НАЖБП) является одной из наиболее распространенных причин повышения содержания сывороточных ферментов при хронических заболеваниях печени (ХЗП). Заболеваемость быстро растет из-за продолжающейся эпидемии ожирения и сахарного диабета типа 2 (СД 2). Это многогранное нарушение обмена веществ встречается в клинической практике различных специалистов здравоохранения: врачей первичного звена и гастроэнтерологов, кардиологов, радиологов и гинекологов. НАЖБП состоит из спектра заболеваний печени - от простого стеатоза до стеатогепатита, который характеризуется стеатозом, лобулярным воспалением, баллонной дистрофией и фиброзом. За последние несколько лет был достигнут значительный прогресс в нашем понимании его факторов риска, патогенеза, течения, неинвазивных маркеров и лечения. Этот обзор ориентирован на врачей, лечащих пациентов с НАЖБП, также обсуждаются практические вопросы, связанные с отдельными аспектами его диагностики.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of the increased contents of serum enzymes in chronic liver diseases. Its incidence rate is associated with the ongoing epidemics of obesity and diabetes of type 2. This multifaceted metabolic disorder is commonly encountered in clinical practice of various health care professionals ranging from primary care providers and gastroenterologists to cardiologists, radiologists and gynecologists. NAFLD comprises a spectrum of liver diseases from simple steatosis to full blown steatohepatitis that is characterized by steatosis, lobular inflammation, ballooning and fibrosis. Over the last several years, much progress has been made in terms of our understanding of its risk factors, pathogenesis, natural history, non-invasive markers and treatment. This review is tailored to clinicians caring for patients with NAFLD and it covers practical issues related to the certain aspects of its evaluation and management.

неалкогольный стеатогепатитдиагностикаnon-alcoholic steatohepatitisdiagnostics

References1

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease / J. Ludvig [et al.] // Mayo Clin. Proc. - 1980. - Vol. 55, № 7. - P. 434-438.

Wieckowska, A. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future / A. Wieckowska, A. J. McCullough, A. E. Feldstein // Hepatology. - 2007. - Vol. 46, № 2. - P. 582-589.

Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies / C. L. Hart [et al.] // Br. Med. J. - 2010. - Vol. 11, № 340. - P. 1240.

Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study / B. Liu [et al.] / [Электронный ресурс] // Br. Med. J. - 2010. - Vol. 340. - P. 912. - Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/20223875. - Дата досупа: 12.12.2010.

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease / A. J. McCullough [et al.] // Clin. Liver. Dis. - 2004. - Vol. 8, № 3. - P. 521-533.

Farrell, G. C. Nonalcoholic fatty liver disease: from steatosis to cirrhosis / G. C. Farrell, C. Z. Larter // Hepatology. - 2006. - Vol. 43, № 2. - Р. 99-112.

Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? / G. Tarantino [et al.] / [Электронный ресурс] // J. Transl Med. - 2008. - Vol. 6, № № 72. - Режим доступа: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2611972/. - Дата доступа: 12.12.2010.

Carter-Kent, C. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment / C. Carter-Kent, N. N. Zein, A. E. Feldstein // Am. J. Gastroenterol. - 2008. - Vol. 103, № 4. - Р. 1036-1042.

Younossi, Z. M. Aliment Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis / Z. M. Younossi // Pharmacol. Ther. - 2008. - Vol. 28, № 1. - Р. 2-12.

Tarantino, G. Should nonalcoholic fatty liver disease be regarded as a hepatic illness only? / G. Tarantino // World J. Gastroenterol. - 2007. - Vol. 13, № 35. - Р. 4669-4672.

Could inflammatory markers help diagnose non-alcoholic steatohepatitis / G. Tarantino // Eur. J. Gastroenterol. Hepatol. - 2009. -Vol. 21, № 5. - Р. 504-511.

Sanyal, A. J. American Gastroenterological Association AGA technical review on nonalcoholic fatty liver disease / A. J. Sanyal // Gastroenterology. - 2002. - Vol. 123, № 5. - Р. 1705-1725.

Edmison, J. Pathogenesis of non-alcoholic steatohepatitis: human data / J. Edmison, A. J. McCullough // Clin. Liver. Dis. - 2007. - Vol. 11, № 1. - Р. 75-104.

Tarantino, G. Hepatic steatosis in overweight/obese females: new screening method for those at risk / G. Tarantino, G. Pizza, A. Colao // World J. Gastroenterol. - 2009. - Vol. 15, № 45. - Р. 5693-5699.

A pilot study of a thiazolidinedione, troglitazone in non-alcoholic steatohepatitis / S. H. Caldwell [et al.] // Am. J. Gastroenterol. - 2001. - Vol. 96, № 2. - Р. 519-525.

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis / L. A. Adams [et al.] // Am. J. Gastroenterol. - 2004. - Vol. 99, № 12. - Р. 2365-2368.

Метаболический синдром / под. ред. чл.-корр. РАМН Г. Е. Ройтберга. - М.: МЕД-пресс-информ, 2007. - 224 с.

Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance / C. Pagano [et al] // J. Clin. Endocrinol. Metab. - 2006. - Vol. 91, № 3. - Р. 1081-1086.

Nonalcoholic steatohepatitis and non-alcoholic Fatty liver disease in young women with polycystic ovary syndrome / T. L. Setji [et al] // J. Clin. Endocrinol. Metab. - 2006. - Vol. 91, № 5. - Р. 1741-1747.

Clinical features and natural history of nonalcoholic steatosis syndromes / Y. Falck-Ytter [et al] // Semin. Liver. Dis. - 2001. - Vol. 21, № 1. - Р. 17-26.

Adams, L. A. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease / L. A. Adams, P. Angulo // Clin. Liver. Dis. - 2007. - Vol. 11, № 1. - Р. 25-35.

Oh, M. K. Review article: diagnosis and treatment of non-alcoholic fatty liver disease / M. K. Oh, J. Winn, F. Poordad // Aliment. Pharmacol. Ther. - 2008. - Vol. 28, № 5. - Р. 503-522.

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes / A. L. Fracanzani [et al.] // Hepatology. - 2008. - Vol. 48, № 3. - Р. 792-798.

Diagnostic value of a computerized hepatorenal index for sonographic quantifcation of liver steatosis / M. Webb [et al.] // Gastrointestinal Imaging. - 2009. - Vol. 192. - Р. 909-914.

The role of Doppler Perfusion Index as screening test in the characterization of focal liver lesions / K. Kyriakopoulou [et al] // Dig. Liver. Dis. - 2008. - Vol. 40, № 9. - Р. 755-760.

Doppler perfusion index (DPI) and homa are highly predictive of fatty liver in patients with NAFLD / M. Dugoni [et al.] // Dig. Liver. Dis. - 2007. - Vol. 40. - P. 39.

One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation / C. K. Ryan [et al.] // Liver. Transpl. - 2002. - Vol. 8, № 12. - Р. 1114-1122.

Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C / A. K. Lim // Gut. - 2005. - Vol. 54, № 1. - Р. 128-133.

Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis / H. Iijima [et al.] // Hepatol. Res. - 2007. - Vol. 37, № 9. - P. 722-730.

Lewis, J. R. Nonalcoholic fatty liver disease: a review and update / J. R. Lewis, S. R. Mohanty // Dig. Dis. Sci. - 2010. - Vol. 55, № 3. - Р. 560-578.

Protocol for measurement of liver fat by computed tomography / L. E. Davidson [et al.] // Appl Physiol. - 2006. - Vol. 100, № 3. - Р. 864-868.

Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment / S. H. Park [et al.] // Radiology. - 2006. - Vol. 239, № 1. - Р. 105-112.

Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT / J. E. Jacobs [et al.] // Am. J. Roentgenol. - 1998. - Vol. 171, № 3. - Р. 659-664.

Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound / M. Fishbein [et al] // J. Clin. Gastroenterol. - 2005. - Vol. 39, № 7. - Р. 619-625.

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population / L. S. Szczepaniak [et al.] // Am. J. Physiol. Endocrinol. Metab. - 2005. - Vol. 288, № 2. - Р. 462-468.

Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T-feasibility / D. P. O’Regan [et al] // Radiology. - 2008. - Vol. 247, № 2. - Р. 550-557.

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. / M. Yoneda [et al.] // J. Gastroenterol. - 2007. - Vol. 42, № 7. - Р. 573-582.

Plasma Pentraxin-3 is a novel marker for nonalcoholic steatohepatitis (NASH). / M. Yoneda [et al] // BMC Gastroenterol. - 2008. - Vol. 14, № 8. - Р. 53.

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis / A. Wieckowska [et al] // Am. J. Gastroenterol. - 2008. - Vol. 103, № 6. - Р. 1372-1379.

Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis / S. K. Satapathy [et al.] // J. Gastroenterol. Hepatol. - 2007. - Vol. 22, № 5. - Р. 634-638.

Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis / G. Tarantino [et al.] // Eur. J. Clin. Invest. - 2007. - Vol. 37, № 1. - Р. 48-53.

Could high levels of tissue polypeptide specific antigen, a marker of apoptosis detected in nonalcoholic steatohepatitis, improve after weight loss? / G. Tarantino [et al.] // Dis. Markers. - 2009. - Vol. 26, № 2. - Р. 55-63.

The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis / B. Degertekin [et al] // Dig. Dis. Sci. - 2007. - Vol. 52, № 10. - Р. 2622-2628.

LIDO Study Group Sampling variability of liver biopsy in nonalcoholic fatty liver disease / V. Ratziu [et al.] // Gastroenterology. - 2005. - Vol. 128, № 7. - Р. 1898-1906.

LIDO Study Group; CYTOL Study Group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease / T. Poynard [et al.] // BMC. Gastroenterol. - 2006. - Vol. 10, № 6. - Р. 34.

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis / T. Poynard [et al.] // Comp. Hepatol. - 2005. - Vol. 23, № 4. - Р. 10.

Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? / T. Poynard [et al.] // Gastroenterology. - 2005. - Vol. 128, № 4. - Р. 1146-1148.

Rockey, D. C. Noninvasive measures of liver fibrosis / D. C. Rockey, D. M. Bissell // Hepatology. - 2006. - Vol. 43, № 1. - Р. 113-120.

Павлов, Ч. С. Современные возможности эластометрии, Фибро- и АктиТеста в диагностике фиброза печени / Ч. С. Павлов, Д. В. Глушенков, В. Т. Ивашкин // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2008. - Т. 18, № 4. - С. 43-52.

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) / M. Yoneda [et al] // Dig. Liver. Dis. - 2008. - Vol. 24, № 40. - Р. 371-378.

Исаков, В. А. Как определять выраженность фиброза печени и зачем? / В. А. Исаков // Клиническая гастроэнтерология и гепатология. - 2008. - Т. 1, № 2. - С. 72-75.

Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis / C. Fierbinteanu-Braticevici [et al.] // World. J. Gastroenterol. - 2009. - Vol. 28, № 15(44). - Р. 5525-5532.

Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography / M. Friedrich-Rust [et al.] // Radiology. - 2009. - Vol. 252, № 2. - Р. 595-604.

Assessment of hepatic fibrosis with magnetic resonance elastography / M. Yin [et al] // Clin. Gastroenterol. Hepatol. - 2007. - Vol. 5, № 10. - Р. 1207-1213.

Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients / G. Tarantino [et al.] // Eur. J. Clin. Pharmacol. -2006. - Vol. 62, № 8. - Р. 605-612.

Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis / C. Fierbinteanu-Braticevici [et al.] // World. J. Gastroenterol. - 2010. - Vol. 16, № 38. - Р. 4784-4791.

The authors declare that there are no conflicts of interest present.